-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ABL-105 in Gastric Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ABL-105 in Gastric Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ABL-105 in Gastric Cancer Drug Details: ABL-105 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ABL-105 in Gastroesophageal (GE) Junction Carcinomas
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ABL-105 in Gastroesophageal (GE) Junction Carcinomas report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ABL-105 in Gastroesophageal (GE) Junction Carcinomas Drug Details: ABL-105 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ABL-105 in Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ABL-105 in Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ABL-105 in...
-
Sector Analysis
BCR-ABL Tests Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033
BCR-ABL Tests Market Overview The BCR-ABL Tests market size was valued at $23.5 million in 2023. The market is expected to grow at a CAGR of more than 5% during 2023-2033. Breakpoint Cluster Region - Tyrosine-Protein Kinase ABL1 fusion gene (BCR-ABL) tests are carried out to detect fusion gene mutations in patient tissue samples. The outcome may guide therapies to treat various cancers including chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), and acute myelogenous leukemia (AML). BCR-ABL Tests Market...
-
Product Insights
Likelihood of Approval Analysis for Female Sexual Dysfunction
Overview How likely is it that the drugs in Female Sexual Dysfunction will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Female Sexual Dysfunction Overview Female sexual dysfunction occurs when a woman...
-
Product Insights
Likelihood of Approval Analysis for Hepatic Encephalopathy
Overview How likely is it that the drugs in Hepatic Encephalopathy will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Hepatic Encephalopathy Overview Hepatic encephalopathy is a worsening of brain function that...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Olverembatinib in Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Olverembatinib in Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Olverembatinib in Chronic Myelocytic Leukemia (CML,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Risvodetinib Succinate in Constipation
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Risvodetinib Succinate in Constipation report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Risvodetinib Succinate in Constipation Drug Details: Risvodetinib succinate (Ikt-148009) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Risvodetinib Succinate in Dysphagia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Risvodetinib Succinate in Dysphagia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Risvodetinib Succinate in Dysphagia Drug Details: Risvodetinib succinate (Ikt-148009) is under development...